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AntiviralsThe C protein of human parainﬂuenza virus type 3 (HPIV3) is a multifunctional accessory protein that
inhibits viral transcription and interferon (IFN) signaling. In the present study, we found that removal of N-
terminal 25 or 50 amino acid residues from the C protein (CNΔ25 or CNΔ50) totally abolished viral RNA
synthesis in the HPIV3 minigenome system. Further N-terminal or C-terminal deletion impaired the
inhibitory ability of CNΔ25 and CNΔ50. Subsequent mutagenesis analysis suggested that the N-terminal-
charged amino acid residues (K3, K6, K12, E16, and R24) contribute to the higher inhibition caused by CNΔ25
than the C protein. Consistent with viral RNA synthesis inhibition, the growth of HPIV3 was signiﬁcantly
decreased by 5 logs in HeLa-derived cell line expressing CNΔ25. Interestingly, replication of respiratory
syncytial virus (RSV), another important respiratory tract pathogen, was also strongly inhibited in the
presence of CNΔ25. These ﬁndings provide a promising potential to use CNΔ25 as an antiviral agent against
the clinically important respiratory tract diseases caused by HPIV3 and RSV.
© 2009 Elsevier Inc. All rights reserved.Introduction
Human parainﬂuenza virus type 3 (HPIV3) is one of the
parainﬂuenza viruses, which is classiﬁed in the subfamily Paramyx-
ovirinae, family Paramyxoviridae, order Mononegavirales (the non-
segmented negative-strand RNA virus). Along with another
respirovirus (HPIV1) and two rubulaviruses (HPIV2 and HPIV4), the
parainﬂuenza viruses (HPIVs) are the most common cause of
respiratory tract diseases, second only to respiratory syncytial virus
(RSV), for infections in young children and infants (e.g. pneumonia,
bronchitis, and bronchiolitis). Infection of HPIVs and RSV has also
been linked to increasing rates of mortality in immuno-compromised
patients (Cortez et al., 2001; Madhi et al., 2002). Although some
antiviral regents and vaccine candidates have been generated and
tested in preclinical and clinical trials (Sato and Wright, 2008; Mao et
al., 2008; Liuzzi et al., 2005; Nichols et al., 2008; Nokes and Cane,
2008), there is no single industry-approved vaccine or antiviral drug
on the market for this group of patients. HPIVs infection is treated
symptomatically, and RSV is treated with nonspeciﬁc antiviral
ribavirin, which is not very effective either in children or in adults
(Nokes and Cane, 2008).
The C protein of HPIV3 is an accessory protein, encoded by the P
gene using an alternative open reading frame. The P gene encodes the
P protein (phosphoprotein), an important cofactor of the viral RNA
polymerase L protein and also the D protein and possibly the Vll rights reserved.protein. The mRNAs of the latter two proteins are thought to be
produced during viral transcription by inserting Gs into an editing site
in the P gene (Durbin et al., 1999). These proteins possess the same N-
terminal amino acid sequences as the P protein but distinct C-termini.
Until now, only the D protein, but not the V protein, has been detected
during HPIV3 infection (Durbin et al., 1999; Galinski et al., 1992;Wells
and Malur, 2008).
The accessory C proteins of paramyxoviruses were reported to be
involved in many of the viral functions, including replication
(Kurotani et al., 1998; Escofﬁer et al., 1999; Sleeman et al., 2008;
Durbin et al., 1999), assembly (Hasan et al., 2000), and budding,
(Sakaguchi et al., 2005), as well as suppressing virus-induced
apoptosis (Koyama et al., 2003; Toth et al., 2009) and antagonizing
host innate immunity (Kato et al., 2001, 2007; Nakatsu et al., 2006,
2008; Malur et al., 2005). Within the paramyxoviruses, only
respiroviruses (e.g. HPIV3, Sedai virus/SeV; Malur et al., 2004; Kato
et al., 2007), morbilliviruses (e.g. measles virus/MV; Nakatsu et al.,
2008), and henipaviruses (e.g. Nipah/NiV; Lo et al., 2009) encode C
proteins. Interestingly, HPIV3, MV, and NiV encode only one C protein,
whereas SeV encodes a set of C proteins (C′, C, Y1, and Y2) through
different translation initiation codons. Although there are very limited
amino acid sequence similarities among these different sources of C
proteins, inhibition of viral replication occurs heterotypically by the C
proteins. For example, HPIV3 C protein inhibits replication of
minigenomes of NiV and MV, whereas C proteins of SeV, but not C
proteins of NiV andMV, inhibit HPIV3minigenome replication (Malur
et al., 2004, Sleeman et al., 2008). As for HPIV3, a coiled–coiled motif
within the C protein was implicated to be involved in the viral
transcription inhibition (Malur et al., 2004). Although the precise
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known, the SeV C protein was reported to inhibit viral replication
by binding to the L protein (Horikami et al., 1997; Grogan and Moyer,
2001), and its N-terminal was dispensable for such inhibition (Kato et
al., 2002, 2004).
In this study, we identiﬁed the domain in HPIV3 C protein
responsible for the inhibition of viral transcription. We found that
CNΔ25 and CNΔ50, the N-terminal 25 and 50 amino acids truncated
mutants of HPIV3 C protein, totally abrogated viral transcription in the
HPIV3 minigenome system, and the inhibitory effect of CNΔ25 in
HPIV3 growth was signiﬁcant. Interestingly, CNΔ25 also strongly
inhibited the replication of RSV. Our ﬁndings suggest that CNΔ25 has a
potential to be used as an effective antiviral agent against the clinically
important respiratory viruses including HPIV3 and RSV.
Results
The domain of HPIV3 C protein that inhibits viral RNA synthesis
To identify the domain of the C protein involved in viral RNA
synthesis inhibition, we constructed a series of plasmids encoding
ﬂag-tagged (C-terminal) C proteins, truncated from both N- and C-
termini (Fig. 1A). We then tested these C mutants, together with the
wild-type (wt) C protein, in the HPIV3 minigenome system as
described in Materials and methods. As previously observed (MalurFig. 1. The domain of the C protein of HPIV3 that inhibits viral RNA synthesis. (A)
Diagram of the N- and C-terminally truncated mutants of the C protein. (B) HPIV3
minigenome assay. The HeLa cells, preinfected with vaccinia virus vTF7-3 to express the
T7 RNA polymerase, were transfected with the minigenome plasmid pMG(−),
supporting plasmids pGEM4-L/pGEM4-P/pGEM4-N as well as the C protein/mutants
encoding plasmids. At 24 h post-transfection, the cells were lysed and the activity of
luciferase was determined using a luminometer. The luciferase activity (%) is a
percentage of the positive control MG(−) after subtracting the background level
MG(−)/−L (L protein is absent in the system). A plasmid-expressing GFP was used
as control for the minigenome system. (C) The cell lysates were detected for the
expression of the ﬂag-tagged C proteins using anti-ﬂag antibody.et al., 2004), the C protein inhibited the luciferase activity by about
60% (Fig. 1B). Surprisingly, N-terminal deletion of 25 amino acids
(CNΔ25) or 50 amino acids (CNΔ50) virtually abolished the
luciferase activity, whereas further deletion (CNΔ100) reduced the
inhibition back to 42%, less than the inhibition caused by the C
protein (60%). In contrast, the deletion from the C-terminal end of
the C protein resulted in the loss of inhibitory ability from 45% for
C1-175 with virtually no inhibition for C1-100. Expression of the C
protein and its mutants was conﬁrmed by Western blot analysis
using the anti-ﬂag antibody (Fig. 1C). The expression levels of the C
and CNΔ25 proteins were comparable, although the CNΔ50 protein
expressed about one half-fold higher (Fig. 1C), suggesting the
different levels of inhibition of viral RNA synthesis caused by C and
CNΔ25 were not due to the amount of proteins expressed. The other
C mutants were expressed in much lower levels than the C protein,
but increasing their expression levels did not signiﬁcantly increase
their inhibitory activities (data not shown). These results suggest
that the C-terminal region of the C protein downstream of residue 25
(CNΔ25) functions in inhibiting viral RNA synthesis, with N-terminal
25 amino acids performing some regulatory role in the inhibition
process.
Deletion mapping of CNΔ25
Since the CNΔ25 protein was able to reproducibly inhibit the
minigenome RNA synthesis, we attempted to identify the minimum
fragment of CNΔ25, without signiﬁcantly losing its inhibitory ability.
We truncated CNΔ25 protein from its C-terminus and generated the
following mutants C26-175, C26-150, C26-125, C26-100, and C26-75
(Fig. 2A). These mutants were tested in HPIV3 minigenome system,
along with the wt C and CNΔ25 proteins. As shown in Fig. 2B, with
increasing deletion from the C-terminus of CNΔ25, the luciferase
activity increased and ﬁnally no inhibition occurred when the C26-75
mutant was present in the minigenome system. Expression levels of
these C proteins were also analyzed by Western blot using the anti-
ﬂag antibody (Fig. 2C). By comparing CNΔ25 and C26-150 proteins,
which were expressed in similar levels, it was evident that the C-
terminal 50 amino acids deletion from CNΔ25 caused the decrease of
the inhibitory activity of CNΔ25. When we compared the effects of
C26-175, C26-125, and C26-75 proteins, which were also comparably
expressed, we found that with the removal of the C-terminal portion,
the inhibitory activity of CNΔ25 was progressively decreased. It is
noteworthy that, although the expression level of the C26-100 protein
was much higher than other C proteins, it only resulted in slight
inhibition (about 16%) of luciferase activity. We further investigated
the relationship between the amounts of protein and the extent of
RNA synthesis inhibition, which showed different does-dependent
curves (data not shown). Consequently, we compared the inhibitory
effects of proteins with similar expression levels instead of using
percent inhibition per unit amount of proteins for any single
experiment. The data were consistent with what was observed for
the C-terminal truncated mutants of the C protein (Fig. 1), suggesting
that the C-terminal region of the C protein is required for the
maximum inhibition of viral RNA synthesis and CNΔ25 manifests
maximum inhibition of viral RNA synthesis.
Interaction of the C protein with the L protein
Since SeV C protein was suggested to inhibit viral transcription by
binding to the viral RNA polymerase (Horikami et al., 1997; Grogan
and Moyer, 2001), we also studied the interaction between HPIV3 C
proteins and viral RNA polymerase L protein using the co-immuno-
precipitation assay. The C-terminally ﬂag-tagged C encoding plasmids
were co-transfected with non-tagged L plasmid into HeLa cells as
described in Materials and methods. Cell lysates harvested at 24 h
post-transfection were incubated with the anti-ﬂag afﬁnity gel
Fig. 4. The role of charged amino acid residues in the N-terminal 25 amino acids of the C
protein in inhibiting the viral RNA synthesis. (A) The N-terminal 25 amino acids of the C
protein, with the charged amino acid residues indicated. (B) The HPIV3 minigenome
assay. The HeLa cells, preinfected with the vaccinia virus vTF 7-3 to express the T7 RNA
polymerase, were transfected with the minigenome plasmid pMG(−), the supporting
plasmids pGEM4-L/pGEM4-P/pGEM4-N, and the C/CNΔ25/site-directed C mutants
expressing plasmids. At 24 h pi, the cells were lysed for the luciferase assay. (C) The
expression of C/CNΔ25/site-directed C mutants was detected by Western blot using
the anti-ﬂag antibody.
Fig. 2. Deletion mapping of CNΔ25. (A) Diagram of the C-terminal truncated mutants of
the CNΔ25 protein. (B) HPIV3 minigenome assay. The HeLa cells, preinfected with
vaccinia virus vTF7-3, were transfected with the minigenome plasmid pMG(−),
supporting plasmids pGEM4-L/pGEM4-P/pGEM4-N as well as C, CNΔ25, or CNΔ25
mutants encoding plasmids. At 24 h post-transfection, the cells were lysed and the
lysates were used to detect luciferase activity. (C) Cell lysates were used for the
detection of the ﬂag-tagged C proteins expression using anti-ﬂag antibody.
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detect ﬂag-tagged C protein (full-length and mutants) and non-
tagged L protein, respectively. As shown in Fig. 3A, ﬂag-C proteins
were pulled down by the anti-ﬂag afﬁnity gel effectively. Simulta-
neously, different amounts of L protein precipitated with the C
proteins (Fig. 3B). To accurately judge the relative efﬁciency of C–L
interaction from blots shown in Fig. 3, we quantiﬁed the intensity ofFig. 3. The interaction between the C protein/mutants and the L protein detected by co-
immunoprecipitation assay. The HeLa cells, preinfected with the vaccinia virus vTF7-3,
were transfected with C protein/mutants encoding plasmids and the L protein
encoding plasmid. At 24 h post-transfection, the cells were lysed and incubated with
the anti-ﬂag M2 afﬁnity gel overnight. The afﬁnity gel was washed and subsequently
boiled with SDS–PAGE loading buffer and was subjected toWestern blot analyses using
anti-ﬂag (A) and anti-L (B) antibodies, respectively. Mock: both L protein and C protein
are absent; L only: C protein is absent. The intensity of each band was quantiﬁed using
ImageQuant 5.2 software, and the L/C ratio wasmeasured as indicated below the ﬁgure.each band using ImageQuant 5.2 software and measured the L/C ratio
as indicated below the ﬁgure. In this experiment, the L/C ratio
represents the interaction afﬁnity between L and C proteins. The L/C
ratio for CNΔ25 and CNΔ50, the two C mutants abrogating the
minigenome transcription, are 0.84 and 0.86, respectively. The C1-100
mutant, which showed no inhibitory effect on minigenome replica-
tion (Fig. 3), only has very weak interaction with L protein (with L/C
ratio of 0.03). Other C mutants with inhibitory ability between C and
C1-100 mutant interact with L protein with different afﬁnities (L/C
ratio: 0.50–0.78). Thus, it seems that the interaction afﬁnity between L
and C correlated, albeit partially, with the inhibitory activity of the C
protein mutants.
Role of charged amino acid residues in the N-terminal 25 amino acids of
the C protein in the inhibition of viral RNA synthesis
Since we did not observe differential L protein binding afﬁnity
between C and CNΔ25 proteins, by the Co-IP assay (Fig. 3A), the
question remains as to how the 25 amino acid residues in the N-
terminus of HPIV3 C protein (Fig. 4A) affect the inhibitory activity of
the C protein on viral RNA synthesis. We initially found that charged
amino acid residues in the C-terminus of the CNΔ25 protein decreased
the inhibition caused by the CNΔ25 protein (data not shown),
suggesting that the net charge of the protein somehow changes its
conformational structure or its interaction with other viral compo-
nents. Accordingly, we substituted the charged amino acid residues
within the N-terminal 25 amino acids of the C protein into alanine
individually, as indicated in the Fig. 4A. The R13 residue was not
included due to lack of expression of the corresponding CR13 protein.
Note that CR24− a mutant of the C protein in which the arginine at
position 24 was substituted with alanine migrated slower during
SDS–PAGE probably due to decreased pI value of CR24 due to
substitution of R to A (Fig. 4C). We then tested these C protein
mutants for transcription inhibition in the HPIV3minigenome system.
We found that all of the C mutants (K3, K6, K12, E16, and R24)
increased the inhibitory activity of the C protein to almost 100%,
Fig. 5. The effects of the C, CNΔ25, and CNΔ50 proteins on HPIV3 growth. (A) The HeLa,
LC-6, CNΔ25, and CNΔ50 cells were infected with mock or HPIV3 (MOI of 0.1) for 24 h.
The cells were lysed for Western blot analysis using the anti-HN and anti-RNP
antibodies to detect the viral proteins HN, P, and N. GAPDH was used as a loading
control. The expression of C/CNΔ25/CNΔ50 proteins was conﬁrmed in the LC-6/
CNΔ25CNΔ50 cells using the anti-ﬂag antibody. (B) The supernatants from samples in A
were titered by plaque assay. The plaque assay for each sample was performed three
times. The average and the standard deviation (SD) of the viral yields are indicated.
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4C), suggesting these N-terminal-charged amino acid residues play a
critical role in the inhibition of viral RNA synthesis.Fig. 6. The effects of the C, CNΔ25, and CNΔ50 proteins on the RSV infection. (A) HeLa, LC-6,
expression of GFP protein in infected cells was observed under the ﬂuorescence microscope. T
white bars represent 100 μm. (B) Cell lysates in A were detected by Western blot using the a
and M/M2. GAPDH was used as a loading control.Effects of the C proteins on HPIV3 growth
Since CNΔ25 and CNΔ50 virtually abolished viral RNA synthesis, it
was of interest to study their effects on viral growth. We established
HeLa-derived stable cell lines expressing CNΔ25 or CNΔ50 using
lentivirus vector and infected the cell lines including C-expressing LC-
6 cells previously described (Malur et al., 2005) with HPIV3 at an MOI
of 0.1. At 24 h post-infection, cells were lysed for immunoblotting
with anti-HN, anti-RNP, or anti-C antibodies, and supernatants were
collected and titered by plaque assay. As shown in Fig. 5A, the
expression of C, CNΔ25, and CNΔ50 proteins was conﬁrmed in the
stable cell lines. Viral glycoprotein HN, as well as P and N proteins,
were slightly higher in LC-6 cells than in parent HeLa cells. In contrast,
all three viral proteins were drastically decreased in CNΔ25- and
CNΔ50-expressing cells. In fact, in CNΔ25 cells, viral proteins were
virtually undetectable by Western blot analysis. Virus titers in the
supernatants showed consistent results (Fig. 5B). In the presence of
CNΔ25 and CNΔ50 proteins, virus titers decreased by 5 logs and 2 logs,
respectively, whereas the C protein had no effect on HPIV3 growth. It
is noteworthy that the amount of viral protein expression in infected
CNΔ50-expressing cells was about 1% of that in infected wt C-
expressing cells, which was consistent with the amount of viruses
produced in CNΔ50-expressing cells (103.7) compared to that in wt C-
expressing cells (105.685, 2 log difference). Thus, it seems that CNΔ25
exerts considerably more inhibitory effect on HPIV3 infection than
CNΔ50.
Effects of the C proteins on the expression of rg-RSV proteins
As mentioned above, HPIV3 C protein heterotypically inhibited the
transcription of MV and NiV within the paramyxovirus family. We
thus wanted to investigate whether CNΔ25 had any effect on the
multiplication of RSV, the most common respiratory pathogen
belonging to the paramyxovirus family. We infected three cell lines
with the GFP-tagged recombinant rg-RSV (Hallak et al., 2000) and at
24 h post-infection, we observed GFP expression in cells under the
ﬂuorescence microscope. We also harvested cell lysates for immuno-
blotting with anti-RSV antibody. As shown in Fig. 6A, GFP expression
was signiﬁcantly and equally inhibited in LC-6, CNΔ25, and CNΔ50CNΔ25, and CNΔ50 cells were infected with mock or gfp-RSV (MOI of 0.1) for 24 h. The
hree sets of pictures are shown, ×5 ﬂuorescence, ×10 ﬂuorescence, and ×10 phase. The
nti-RSV virion antibody for the expression of the viral proteins including the G, F1/N, P,
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proteins G and F1/N were undetectable, and the P protein was also
signiﬁcantly decreased in three infected cell lines (Fig. 6B). Interest-
ingly, viralM/M2 proteins were comparable in all cells. The signiﬁcant
inhibition of viral protein synthesis strongly suggests that the CNΔ25
protein as well as C and CNΔ50 proteins also possesses potent
antiviral activity against RSV infection.
Discussion
The paramyxoviral C protein is a multifunctional protein involved
in regulating various viral and cellular functions (Kurotani et al., 1998;
Escofﬁer et al., 1999; Sleeman et al., 2008; Dubin et al., 1999; Hasan et
al., 2000; Sakaguchi et al., 2005; Koyama et al., 2003; Toth et al., 2009;
Kato et al., 2001, 2007; Nakatsu et al., 2006, 2008; Malur et al., 2005).
The major studies on the C proteins have been directed towards
exploring their inhibitory roles in viral transcription and counter-
acting IFN signaling pathways (Grogan and Moyer, 2001; Horikami et
al., 1997; Kato et al., 2002, 2004, 2001, 2007; Malur et al., 2004; Malur
et al., 2005; Nakatsu et al., 2006; Nakatsu et al., 2008; Sleeman et al.,
2008). Using a reporter gene carryingminigenome transcription assay
(Hoffman and Banerjee, 2000), we demonstrated that HPIV3 C protein
inhibits viral transcription by 60% and identiﬁed a coil–coil motif
within the protein, the removal of which resulted in signiﬁcant
abrogation of the inhibitory function (Malur et al., 2004). In the
present study, we demonstrated that removal of N-terminal 25 or 50
amino acids of the C proteins (CNΔ25 and CNΔ50) completely
inhibited viral transcription in HPIV3 minigenome system (Fig. 1),
whereas further N-terminal deletion (CNΔ100) impaired the inhib-
itory activity of the C protein, suggesting that C50-100 fragment is
critical for the inhibitory activity of C protein. These ﬁndings are
consistent with our previous observation that a coil–coil structure of
the C protein, C60-80, played a critical role in the inhibition of viral
transcription (Malur et al., 2004). However, the mutants C26-75 and
C26-100 (overlapping or containing C60-80) exerted less effect on
minigenome transcription (Fig. 2). Moreover, progressive deletion
from the C-terminal end of CNΔ25 resulted in gradual loss of the
inhibitory effect (Figs. 1 and 2), suggesting that C-terminal region also
plays a role in the inhibition process. Altering the charged amino acids
within the N-terminal 25 amino acids of the full-length C protein to
alanine rendered C protein to strongly inhibit transcription similar to
CNΔ25 (Fig. 4). Thus, it seems that the overall structure of the C
protein, rather than the single peptide, correlates with the RNA
synthesis inhibition phenotype.
To further explore the mechanism by which CNΔ25 inhibits RNA
synthesis, we studied its interaction with the L protein. Previously, it
has been shown for SeV that the inhibition of viral RNA synthesis by
the C protein directly correlated with its interaction with the L protein
(Horikami et al., 1997; Grogan andMoyer, 2001). Our studies similarly
demonstrated that HPIV3 C as well as CNΔ25 and CNΔ50 bound to the
L protein to a similar extent (Fig. 3), whereas the C-terminally deleted
C that are less inhibitory to RNA synthesis interacted to the L protein in
signiﬁcantly lesser degree. The cogent question remains as to why
CNΔ25 and CNΔ50, which bind similarly to the L protein as wt C, exert
such a different RNA inhibitory phenotype in theminigenome assay. It
can be envisaged that these two proteins manifest different functional
attributes during RNA synthesis inhibition by their altered structural
conformation or interacting differently with the essential cofactor, the
P protein, although the later protein also interact with the wt C and
CNΔ25 to the same extent (data not shown). Thus, the precise
mechanism by which CNΔ25 and CNΔ50 inhibit transcription so
dramatically needs further studies.
The interesting and potential clinically important ﬁndings are that
particularly CNΔ25 appears to function as a potent antiviral protein.
We established stable cell lines expressing CNΔ25 and CNΔ50 using
lentiviral system similar to that previously established for the wt Cprotein, LC6 cells (Malur et al., 2005). The growth of HPIV3 was
severely restricted in CNΔ25-expressing cells both in viral protein
synthesis and in virus yields (Fig. 5). The inhibition of viruses was by 5
logs in CNΔ25 cells, whereas the viral growth was inhibited by 2 logs
in CNΔ50 and no inhibition was observed in LC6 cells. These results
reinforce the contention that the mode of CNΔ25-mediated inhibition
of viral RNA synthesis must be different from the observed inhibition
by the wt C protein and possibly CNΔ50. Interestingly, CNΔ25-
expressing cells also inhibited replication of GFP-expressing RSV (Fig.
6). The viral protein synthesis, speciﬁcally G and F1/N, was greatly
inhibited. However, we did not observe any plaque formed in plaque
assay, even by the supernatant harvested from infected HeLa cells. The
reason for this might be due to rg-RSV being severely attenuated than
wt RSV (data not shown). The precise reason for the inhibitory
property of CNΔ25 on RSV replication remains unclear; however,
heterotypic inhibition of RNA synthesis by paramyxoviral C proteins
has been well documented (Sleeman et al., 2008).
In summary, removal of the N-terminal 25 amino acids of the C
protein (CNΔ25) signiﬁcantly potentiated the inhibitory activity of
the C protein on viral transcription. The charged amino acid residues
K3, K6, K12, E16, and R24 within the N-terminal 25 amino acids
appear to be involved in the regulation of transcription inhibition.
Remarkably, CNΔ25 acts as a potent inhibitor against the infection of
both of HPIV3 and RSV, raising a possibility that the CNΔ25 can be
used as an antiviral agent in future studies.
Materials and methods
Cells and viruses
HeLa (S) cells were cultured in DMEM (10% fetal bovine serum,
penicillin/streptomycin). HeLa-derived stable cell lines expressing C
protein (LC-6; Malur et al., 2005), CNΔ25, and CNΔ50 cells were
established using recombinant lentiviruses, and single cell clones
were obtained through blasticidin selection followed by puriﬁcation
through limited dilution. HPIV3 (HA-1; NIH 47885) and vesicular
stomatitis virus/VSV (Indiana) were grown in HeLa cells. The
recombinant GFP-tagged RSV (rg-RSV) was generously supplied by
Dr. Brian R. Murphy in the National Institute of Allergy and Infectious
Diseases (NIAI.D).
HPIV3 minigenome assay
HPIV3 minigenome assay was performed as described previously
(Mao et al., 2008; Hoffman and Banerjee, 2000) with slight modiﬁca-
tions.HeLacellmonolayers in 6-well plate, grown to70–80%conﬂuence,
were infected with recombinant vaccinia virus vTF7-3, which expresses
T7 RNA polymerase, at an MOI of 2. At 1 h post-infection, cells were
washed with phosphate-buffered saline (PBS) and transfected with
HPIV3 minigenome plasmid pMG(−) (200 ng) encoding luciferase
reporter gene, supportingplasmidsencodingN(640ng), P (700ng), and
L (100 ng) proteins as well as the C/mutants expressing plasmids
(500 ng) using Lipofectin (Invitrogen). MG(−)/−L was used as the
negative control in which the L-expressing plasmid was absent. At 24 h
post-transfection, cells were lysed in 100 μl of lysis buffer, from which
20 μl aliquotswas used todetermine luciferase activity in a luminometer
(VICTOR) according to themanufacturer's instructions (LuciferaseAssay
Kit; Roche).
Western blotting
Western Blotting was performed according to the protocol reported
previously (Mao et al., 2008) with slight modiﬁcations. In brief, cell
extractswere subject to 10% sodiumdodecyl sulfate–polyacrylamidegel
electrophoresis (SDS–PAGE) and transferred to nitrocellulose mem-
brane. The membrane was blocked with 5% nonfat milk in PBST (PBS
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nonfat milk at 4 °C for overnight. The anti-ﬂag antibody was purchased
from Sigma. The anti-L antibody was prepared from a rabbit by the
Hybridoma Core in the Lerner Research Institute (Chattopadhyay and
Banerjee, 2009). The substrate reaction was performed using ECL™
Western blotting detection kit (GE Healthcare).
Co-immunoprecipitation assay
The co-immunoprecipitation assay was performed as described
previously (Chattopadhyay and Banerjee, 2009). In brief, HeLa cells
were infected with the recombinant vaccinia virus, vTF7-3, and
plasmids encoding L protein (2.5 μg), and C-terminally ﬂag-tagged C
protein (0.5 μg) or C mutant proteins (0.5 μg) were co-transfected
using Lipofectin (Invitrogen). At 24 h post-transfection, the cells were
lysed in the lysis buffer (Roche). The cell lysates were incubated with
the anti-ﬂag M2 afﬁnity gel (Sigma A2220) at 4 °C overnight. The
afﬁnity gel was washed with Tris-buffered saline (TBS) for ﬁve times
and subsequently boiled in the presence of 5×loading buffer. The
immunoprecipitated proteins were resolved in SDS–PAGE gel and
transferred to a nitrocellulose membrane by Western blotting. The
nitrocellulose membrane containing transferred proteins was incu-
bated with either anti-L polyclonal antibody or anti-ﬂag M2
monoclonal antibody (Sigma F3165) followed by incubation with
appropriate secondary antibodies for the detection of L or C proteins
by chemiluminescence (GE healthcare).
Mutagenesis
Mutagenesis was performed using Quick-Change® II site-directed
kit (Stratagene, #200523). In brief, primer pairs were used to amplify
site-mutated C genes by Ultra polymerasewith the C protein encoding
plasmids as the template. The products were treated with DpnI (1u) at
37 °C for 1 h to digest the methylated template. One microliter of
sample was used to transform XL-1 Blue competent cells. Colonies
were identiﬁed by restriction enzyme digestion and conﬁrmed by
sequencing.
Plaque assay for HPIV3
The virus titer was determined by plaque assay as described
previously (Mao et al., 2008). Brieﬂy, the supernatant of the infected
cells was serially diluted in 1ml of OPTI-MEM. Conﬂuentmonolayer of
CV1 cells in 6-well plates was washed with PBS and incubated with
the diluted suspension at 37 °C, 5% CO2 for 1.5 h. The media were then
removed and cells were washed with PBS and overlaid with 0.8%
methylcellulose. After 48 h, themethylcellulose was aspirated and the
cells were stained with 1% crystal violet (in 50% methanol).
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